
  
    
      
        
        Lassa_NNP fever_NN ,_, a_DT viral_JJ hemorrhagic_JJ fever_NN caused_VBN by_IN the_DT Lassa_NNP virus_NN and_CC commonly_RB
        transmitted_VBN by_IN its_PRP$ rodent_NN host_NN ,_, is_VBZ endemic_JJ in_IN certain_JJ areas_NNS of_IN West_NNP Africa_NNP ,_, where_WRB several_JJ
        hundred_CD thousand_CD people_NNS are_VBP estimated_VBN to_TO be_VB infected_VBD each_DT year_NN ._. The_DT disease_NN is_VBZ asymptomatic_JJ
        or_CC mild_JJ in_IN approximately_RB 80_CD %_NN of_IN infected_JJ patients_NNS ,_, but_CC the_DT remaining_VBG 20_CD %_NN have_VBP severe_JJ
        multisystem_NN disease_NN ._. Estimated_VBN overall_JJ mortality_NN is_VBZ 1_CD %_NN –_NN 2_CD %_NN ._.
        Death_NN rates_NNS are_VBP particularly_RB high_JJ for_IN women_NNS in_IN the_DT third_JJ trimester_NN of_IN pregnancy_NN ,_, and_CC for_IN
        fetuses_NNS ,_, about_IN 95_CD %_NN of_IN which_WDT die_VBP in_IN the_DT uterus_NN of_IN infected_JJ pregnant_JJ mothers_NNS ._. The_DT most_RBS common_JJ
        complication_NN of_IN Lassa_NNP fever_NN is_VBZ deafness_NNS ._. Various_JJ degrees_NNS of_IN deafness_NNS occur_VBP in_IN approximately_RB
        one-third_NN of_IN cases_NNS ,_, and_CC in_IN many_JJ cases_NNS hearing_NN loss_NN is_VBZ permanent_JJ ._. Disease_NN severity_NN does_VBZ not_RB
        seem_VB to_TO affect_VB this_DT complication_NN :_: deafness_NNS may_MD develop_VB in_IN mild_JJ as_IN well_RB as_IN in_IN severe_JJ
        cases_NNS ._.
        Lassa_NNP fever_NN remains_VBZ a_DT serious_JJ challenge_NN to_TO public_JJ health_NN in_IN West_NNP Africa_NNP ,_, threatening_VBG
        both_DT local_JJ residents_NNS in_IN rural_JJ areas_NNS and_CC those_DT who_WP serve_VBP them_PRP ,_, particularly_RB medical_JJ care_NN
        providers_NNS ._. Ribavirin_NNP ,_, an_DT antiviral_JJ drug_NN ,_, has_VBZ been_VBN used_VBN successfully_RB in_IN Lassa_NNP fever_NN
        patients_NNS ,_, but_CC it_PRP needs_VBZ to_TO be_VB given_VBN early_JJ and_CC is_VBZ not_RB readily_RB available_JJ in_IN the_DT infected_JJ
        areas_NNS ._. Given_VBN the_DT ecology_NN of_IN the_DT rodent_NN host_NN and_CC conditions_NNS in_IN the_DT endemic_JJ area_NN ,_, a_DT vaccine_NN
        is_VBZ mandatory_JJ for_IN control_NN ._. Lassa_NNP vaccine_NN initiatives_NNS have_VBP suffered_VBN from_IN a_DT lack_NN of_IN funding_NN in_IN
        the_DT past_NN ,_, but_CC bioterrorism_NN and_CC recent_JJ importation_NN of_IN the_DT disease_NN to_TO the_DT United_NNP States_NNPS and_CC
        Europe_NNP have_VBP brought_VBN new_JJ resources_NNS to_TO Lassa_NNP virus_NN science_NN ._.
        Early_RB attempts_VBZ to_TO develop_VB a_DT Lassa_NNP fever_NN vaccine_NN in_IN the_DT 1980_CD s_VBZ focused_VBN on_IN killed_VBN
        pathogens_NNS ,_, which_WDT caused_VBD a_DT strong_JJ humoral_NN response_NN but_CC failed_VBD to_TO protect_VB nonhuman_NN primate_NN
        test_NN animals_NNS ._. Subsequently_RB ,_, recombinant_JJ vaccines_NNS used_VBD vaccinia_NN vectors_NNS carrying_VBG different_JJ
        combinations_NNS of_IN structural_JJ Lassa_NNP proteins_NNS ._. Some_DT of_IN these_DT protected_VBN 90_CD %_NN of_IN nonhuman_NN primates_NNS
        from_IN a_DT lethal_JJ challenge_NN in_IN the_DT absence_NN of_IN a_DT strong_JJ humoral_NN response_NN ,_, suggesting_VBG that_IN
        cellular_JJ responses_NNS are_VBP important_JJ for_IN protection_NN ._.
        Use_NN of_IN vaccinia_NN vectors_NNS in_IN humans_NNS is_VBZ problematic_JJ ,_, especially_RB in_IN areas_NNS where_WRB HIV_NNP
        infection_NN is_VBZ common—immune-suppressed_JJ individuals_NNS can_MD develop_VB serious_JJ skin_NN lesions—and_NN
        several_JJ alternative_JJ vaccines_NNS based_VBN on_IN other_JJ vectors_NNS as_RB well_RB as_IN harmless_JJ vaccinia_NN ones_NNS are_VBP
        under_IN development_NN ._. Thomas_NNP Geisbert_NNP and_CC colleagues_NNS now_RB report_VBP promising_JJ results_NNS with_IN a_DT
        replication-competent_JJ vaccine_NN based_VBN on_IN attenuated_JJ recombinant_JJ vesicular_NN stomatitis_NNS virus_NN
        vectors_NNS expressing_VBG the_DT Lassa_NNP viral_JJ glycoprotein_NN ._. A_DT single_JJ intramuscular_NN vaccination_NN
        protected_VBD all_DT four_CD vaccinated_JJ cynomolgus_JJ macaques_NNS against_IN a_DT lethal_JJ challenge_NN of_IN a_DT
        particular_JJ Lassa_NNP strain_NN ,_, while_IN two_CD control_NN monkeys_NNS that_WDT had_VBD received_VBN empty_JJ vector_NN died_VBD
        after_IN injection_NN with_IN the_DT same_JJ dose_NN of_IN virus_NN ._.
        These_DT are_VBP encouraging_VBG results_NNS ,_, but_CC future_JJ larger_JJR studies_NNS will_MD need_VB to_TO assess_VB the_DT
        duration_NN of_IN protection_NN and_CC demonstrate_VB the_DT safety_NN of_IN this_DT replication-competent_JJ vaccine_NN ._.
        Another_DT crucial_JJ question_NN is_VBZ how_WRB quickly_RB vaccinated_JJ individuals_NNS acquire_VB protection_NN ,_, and_CC thus_RB
        whether_IN the_DT vaccine_NN would_MD be_VB suitable_JJ for_IN creating_VBG a_DT ring_NN of_IN vaccination_NN around_IN an_DT outbreak_NN
        zone_NN ,_, the_DT most_RBS likely_JJ early_JJ application_NN of_IN a_DT promising_JJ candidate_NN vaccine_NN ._. In_IN addition_NN ,_,
        there_RB are_VBP at_IN least_JJS four_CD different_JJ strains_NNS of_IN the_DT Lassa_NNP virus_NN ,_, and_CC an_DT ideal_JJ vaccine_NN should_MD
        provide_VB protection_NN across_IN all_DT strains_NNS ._. Finally_RB ,_, conducting_VBG trials_NNS in_IN endemic_JJ areas_NNS ,_, many_JJ of_IN
        which_WDT lack_VBP political_JJ stability_NN ,_, remains_VBZ a_DT serious_JJ challenge_NN ._.
      
    
  
